Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ECCO 15 - ESMO 34 /
New targeted drugs for metastatic renal cell carcinoma

20th - 24th Sep 2009

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 25.09.09
Views: 11479

Dr Joaquim Bellmunt - Section Chief, Solid Tumor Oncology, Hospital del Mar, Barcelona, Spain

Expert interview with Dr Joaquim Bellmunt MD PhD conducted by Prof Gordon McVie

Context / Quiz

New targeted drugs for metastatic renal cell carcinoma

Target audience:

This educational activity is intended for medical, surgical and radiation oncologists, as well as allied oncology professionals who treat renal cell carcinoma.

Statement of need:

Metastatic renal cell carcinoma (RCC) has poor outcomes. Metastatic disease is resistant to radiation therapy and chemotherapy, although some cases respond to immunotherapy. Although targeted cancer therapies have improved progression-free survival for RCC they have not yet demonstrated much improvement in overall survival. What next after failure of these drugs? An educational need exists to assist physicians in the sequential use of novel treatments, or perhaps in the future, in combinations. The management of metastatic renal cell carcinoma has become more challenging and more complicated because some therapeutic successes have been reported in this stubborn cancer.

Learning objective:

After watching this expert interview participants should be able to:

  • Understand the pathophysiology of renal cancer, newly detected cancer associated molecular targets and new therapeutics designed to lock on to those receptors or cellular proteins.
  • Have insight into the use of the new molecules, in sequence, in combination with other modalities such as immunomodulators, or in combination with each other, together with expectations of side effects and gains in symptom/free survival when given to patients with metastatic or locally progressive renal cancer.


This scientific information may include data/information on investigational uses of compounds/drugs that have not yet been approved by regulatory authorities.

This material was developed for use outside of the US and is to be used in accordance with local laws and regulations.

Supported by an unrestricted educational grant from Novartis

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation